DE60330362D1 - Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf) - Google Patents

Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)

Info

Publication number
DE60330362D1
DE60330362D1 DE60330362T DE60330362T DE60330362D1 DE 60330362 D1 DE60330362 D1 DE 60330362D1 DE 60330362 T DE60330362 T DE 60330362T DE 60330362 T DE60330362 T DE 60330362T DE 60330362 D1 DE60330362 D1 DE 60330362D1
Authority
DE
Germany
Prior art keywords
tgf
inhibitor
growth factor
transforming growth
pyrazol compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60330362T
Other languages
English (en)
Inventor
Michael John Munchhof
Laura Cook Blumberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of DE60330362D1 publication Critical patent/DE60330362D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
DE60330362T 2002-09-18 2003-09-08 Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf) Expired - Lifetime DE60330362D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41214602P 2002-09-18 2002-09-18
US48454303P 2003-07-02 2003-07-02
PCT/IB2003/003933 WO2004026306A2 (en) 2002-09-18 2003-09-08 Pyrazole derivatives as transforming growth factor (tgf) inhibitors

Publications (1)

Publication Number Publication Date
DE60330362D1 true DE60330362D1 (de) 2010-01-14

Family

ID=32033585

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60330362T Expired - Lifetime DE60330362D1 (de) 2002-09-18 2003-09-08 Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)

Country Status (27)

Country Link
US (4) US6958354B2 (de)
EP (2) EP2165708A3 (de)
JP (1) JP4519657B2 (de)
KR (1) KR20050044807A (de)
CN (1) CN1681501A (de)
AP (1) AP2005003263A0 (de)
AR (1) AR041272A1 (de)
AT (1) ATE450258T1 (de)
AU (1) AU2003259475A1 (de)
BR (1) BR0314302A (de)
CA (1) CA2496295C (de)
CO (1) CO5550456A2 (de)
DE (1) DE60330362D1 (de)
EA (1) EA200500377A1 (de)
EC (1) ECSP055679A (de)
ES (1) ES2335099T3 (de)
HR (1) HRP20050247A2 (de)
IS (1) IS7698A (de)
MA (1) MA27440A1 (de)
MX (1) MXPA05002376A (de)
NO (1) NO20050838L (de)
OA (1) OA12929A (de)
PA (1) PA8583201A1 (de)
PE (1) PE20040988A1 (de)
PL (1) PL375979A1 (de)
UY (1) UY27985A1 (de)
WO (1) WO2004026306A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP2005003261A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
AP2005003264A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
PL375979A1 (en) * 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)
GB0313915D0 (en) * 2003-06-16 2003-07-23 Smithkline Beecham Corp Compounds
CA2578628A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as tgf-beta inhibitors
WO2006028029A1 (ja) * 2004-09-07 2006-03-16 Sankyo Company, Limited 置換ビフェニル誘導体
CA2584248A1 (en) * 2004-10-15 2006-04-27 Biogen Idec Ma Inc. Methods of treating vascular injuries
TW200639163A (en) * 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
CA2629432A1 (en) * 2005-12-16 2007-06-21 Alcon, Inc. Control of intraocular pressure using alk5 modulation agents
PT2089367E (pt) 2006-10-31 2012-02-01 Pfizer Prod Inc Compostos de pirazolina como antagonistas dos receptores mineralcorticóides
AU2008281543A1 (en) * 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as Raf inhibitors
ES2813875T3 (es) 2014-01-01 2021-03-25 Medivation Tech Llc Compuestos y procedimientos de uso
WO2016160881A1 (en) 2015-04-01 2016-10-06 Rigel Pharmaceuticals, Inc. TGF-β INHIBITORS
WO2016210292A1 (en) 2015-06-25 2016-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
AU2017235461B2 (en) 2016-03-15 2023-02-23 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
EP3470409B1 (de) * 2016-06-13 2020-02-12 Genfleet Therapeutics (Shanghai) Inc. Alpha und beta-ungesättigte amidverbindung aus benzotriazol als tgf-beta ri-inhibitor
EP3532604A4 (de) * 2016-10-26 2020-06-03 Icahn School of Medicine at Mount Sinai Verfahren zur erhöhung der zellproliferation in pankreatischen beta-zellen, behandlungsverfahren und zusammensetzung
BR112019008516A2 (pt) 2016-11-14 2019-07-09 Jiangsu Hengrui Medicine Co derivado de 3,4-bipiridil pirazol, e método de preparação para o mesmo e aplicação médica do mesmo
US11547712B2 (en) 2017-11-20 2023-01-10 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
RU2750702C1 (ru) * 2017-12-13 2021-07-01 Джинфлит Терапьютикс (Шанхай) Инк. КРИСТАЛЛИЧЕСКАЯ ФОРМА И СОЛЕВАЯ ФОРМА ИНГИБИТОРА TGF-βRI И СПОСОБ ИХ ПОЛУЧЕНИЯ
US11788064B2 (en) 2018-01-05 2023-10-17 Icahn School Of Medicine At Mount Sinai Method of increasing proliferation of pancreatic beta cells, treatment method, and composition
CA3093340A1 (en) 2018-03-20 2019-09-26 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
TW202012390A (zh) * 2018-06-29 2020-04-01 日商日本歐愛特農業科技股份有限公司 新穎之經取代吡唑衍生物
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TW202039459A (zh) 2018-12-11 2020-11-01 美商施萬生物製藥研發 Ip有限責任公司 Alk5 抑制劑
CN110467601B (zh) * 2019-08-29 2021-07-02 杭州市西溪医院 一种吡唑联吡啶酮类化合物、中间体及其制备方法及应用
US11590116B2 (en) 2019-11-22 2023-02-28 Theravance Biopharma R&D Ip, Llc Substituted pyridines and methods of use

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (de) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4925857A (en) * 1989-03-22 1990-05-15 Sterling Drug Inc. Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
JP3734180B2 (ja) * 1994-12-28 2006-01-11 エーザイ株式会社 新規ピラゾール誘導体
US6514977B1 (en) 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6087381A (en) 1997-05-22 2000-07-11 G. D. Searle & Company Pyrazole derivatives as p38 kinase inhibitors
US5932576A (en) 1997-05-22 1999-08-03 G. D. Searle & Company 3(5)-heteroaryl substituted pyrazoles as p38 kinase inhibitors
JP2002541253A (ja) 1999-04-09 2002-12-03 スミスクライン・ビーチャム・コーポレイション トリアリールイミダゾール
AR029803A1 (es) 2000-02-21 2003-07-16 Smithkline Beecham Plc Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden
GB0007405D0 (en) 2000-03-27 2000-05-17 Smithkline Beecham Corp Compounds
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
EP1349851A4 (de) 2000-11-16 2004-09-08 Smithkline Beecham Corp Verbindungen
GB0027987D0 (en) 2000-11-16 2001-01-03 Smithkline Beecham Plc Compounds
GB0100762D0 (en) 2001-01-11 2001-02-21 Smithkline Beecham Plc Novel use
ES2237671T3 (es) * 2001-02-02 2005-08-01 Smithkline Beecham Corporation Derivados de pirazol contra la sobreexpresion de tgf.
JP2004521901A (ja) * 2001-02-02 2004-07-22 グラクソ グループ リミテッド Tgf阻害剤としてのピラゾール
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
AP2002002460A0 (en) 2001-03-09 2002-06-30 Pfizer Prod Inc Novel benzimidazole anti-inflammatory compounds.
ATE402164T1 (de) 2001-04-26 2008-08-15 Eisai R&D Man Co Ltd Stickstoffhaltige verbindung mit kondensiertem ring und pyrazolylgruppe als substituent und medizinische zusammensetzung davon
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
AR040726A1 (es) 2002-07-31 2005-04-20 Smithkline Beecham Corp Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento
AP2005003264A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel imidazole compounds as transforming growth factor (TGD) inhibitors.
AP2005003261A0 (en) 2002-09-18 2005-03-31 Pfizer Prod Inc Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors.
PL375979A1 (en) 2002-09-18 2005-12-12 Pfizer Products Inc. Pyrazole derivatives as transforming growth factor (tgf) inhibitors
CA2497971A1 (en) 2002-09-18 2004-04-01 Pfizer Products Inc. Triazole derivatives as transforming growth factor (tgf) inhibitors
EA200500286A1 (ru) 2002-09-18 2005-08-25 Пфайзер Продактс Инк. Новые изотиазольные и изоксазольные соединения в качестве ингибиторов трансформирующего фактора роста (тфр)
PA8595001A1 (es) 2003-03-04 2004-09-28 Pfizer Prod Inc Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf)

Also Published As

Publication number Publication date
CA2496295C (en) 2010-11-23
PE20040988A1 (es) 2004-12-25
US20100056571A1 (en) 2010-03-04
AU2003259475A1 (en) 2004-04-08
CA2496295A1 (en) 2004-04-01
PL375979A1 (en) 2005-12-12
AP2005003263A0 (en) 2005-03-31
ATE450258T1 (de) 2009-12-15
IS7698A (is) 2005-02-17
CN1681501A (zh) 2005-10-12
NO20050838L (no) 2005-05-18
OA12929A (en) 2006-10-13
UY27985A1 (es) 2004-04-30
US20060025451A1 (en) 2006-02-02
EA200500377A1 (ru) 2005-08-25
WO2004026306A2 (en) 2004-04-01
PA8583201A1 (es) 2004-04-23
MA27440A1 (fr) 2005-07-01
CO5550456A2 (es) 2005-08-31
ECSP055679A (es) 2005-05-30
EP2165708A2 (de) 2010-03-24
US20070117850A1 (en) 2007-05-24
EP2165708A3 (de) 2010-07-28
WO2004026306A3 (en) 2004-07-01
JP2006507353A (ja) 2006-03-02
US7151110B2 (en) 2006-12-19
AR041272A1 (es) 2005-05-11
US7638537B2 (en) 2009-12-29
ES2335099T3 (es) 2010-03-22
US6958354B2 (en) 2005-10-25
JP4519657B2 (ja) 2010-08-04
BR0314302A (pt) 2005-07-05
EP1542684B1 (de) 2009-12-02
KR20050044807A (ko) 2005-05-12
MXPA05002376A (es) 2005-05-23
HRP20050247A2 (en) 2005-10-31
US20040116474A1 (en) 2004-06-17
EP1542684A2 (de) 2005-06-22

Similar Documents

Publication Publication Date Title
DE60330362D1 (de) Neue pyrazol-verbindungen als hemmer des transformierenden wachstumsfaktors (tgf)
DE60327443D1 (de) Neue oxazolverbindungen als inhibitoren des transforming growth factor (tgf)
DE60328028D1 (de) Imidazolverbindungen als inhibitoren des transformierenden wachstumsfaktors (twf)
DE60321324D1 (de) Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
ATE294805T1 (de) Triazoloverbindungen als mmp-inhibitoren
CY1106247T1 (el) Θειοφαινο- και θειαζολοσουλφοναμιδες ως αντινεοπλαστικοι παραγοντες
ATE446093T1 (de) Substituierte chinazolin-derivate als aurora- kinase inhibitoren
ATE537843T1 (de) Neue kinase-hemmer
DK1355644T3 (da) Anvendelse af substituerede azetidinonforbindelser til behandling af sitosterolæmi
DE60120198D1 (de) Pyrazolverbindungen als protein-kinasehemmer
DE60119777D1 (de) Pyrazolverbindungen als protein-kinasehemmer
GB0127903D0 (en) Improvements relating to organic compounds
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
DE50107316D1 (de) Neue substituierte imidazotriazinone als pde ii-inhibitoren
DE60210612D1 (de) N-formylhydroxylamin verbindungen als inhibitoren von pdf
ATE411287T1 (de) Neue metallproteinaseinhibitoren
ATE434619T1 (de) Thienodibenzazulenverbindungen als tumornekrosefaktorhemmer
DE602004026905D1 (de) 2-aminoaryloxazol-verbindungen als tyrosinkinase-hemmer
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
DE60239924D1 (de) Cyclopropaheterocyclen als nicht-nukleosidische hemmer der reversen transkriptase
ATE348606T1 (de) Neue verwendung von pipatalin

Legal Events

Date Code Title Description
8364 No opposition during term of opposition